Efficacy of Home-based Treatment for Breast Cancer-related Lymphedema
1 other identifier
interventional
40
1 country
1
Brief Summary
The goal of this clinical trials is to explore the effectiveness of home-based iymphedema treatment and the differences between the home-based and outpatient treatment. The main question is to verify that home-based treatment is as effective as outpatient treatment. We set two groups in this study, comparing the volume of affected upper limb to see if home-based iymphedema treatment is valuable method.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Nov 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 13, 2024
CompletedFirst Submitted
Initial submission to the registry
January 5, 2025
CompletedFirst Posted
Study publicly available on registry
January 20, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 13, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 13, 2025
CompletedJanuary 20, 2025
January 1, 2025
1 year
January 5, 2025
January 14, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the volum of affected arm
A soft ruler was used to measure the patient's wrist stripes and 10cm, 20cm, 30cm and 40cm above the wrist stripes, respectively, to obtain the circumference value. The five measurement points can divide the limb into four truncated cones, and then the formula can be used to calculate the volume of each limb segment, in which C1 and C2 are the arm circumference of the upper and lower two points of the measurement segment. h is the length of the measuring section, that is, 10 cm, and the whole limb volume is the sum of the volumes of each section.
at the first day and after one month
Secondary Outcomes (2)
Quality of life Core questionnaire scale -- EORTC QLQ-C30
at the first day and after one month
Breast Cancer and Lymphedema Symptom Experience Index, BCLE-SEI
at the first day and after one month
Study Arms (2)
home-based group
EXPERIMENTALIn this group of patients, the therapist conducted standardized comprehensive detumescence treatment at the first treatment which including four steps of skin care, manual lymphatic drainage, low-elastic bandage dressing and functional exercise. After the treatment, videos of manual lymphatic drainage and pressure dressing of family members were provided. Patients or family members were required to perform this treatment at home every day. Video recordings were necessary during treatment at home which were required be sent to the therapist, making sure the session is done every day. They returned to the edema clinic one month later for another evaluation. If patients encounter problems that cannot be solved during home treatment, they should consult online on wechat, or return to the edema clinic in time.
outpatient group
ACTIVE COMPARATORPatients were required to go to the lymphedema clinic for comprehensive detumescence treatment, including skin care, manual lymphatic drainage, low-elastic bandaging and functional exercise, 3 to 5 times a week for 1 hour each time. They were re-evaluated after one month of treatment.
Interventions
Comprehensive detumescence treatment, including skin care, manual lymphatic drainage, low elastic bandaging and functional exercise four steps
Three to five times a week, one hour each time
Eligibility Criteria
You may qualify if:
- Lymphedema appeared in the upper limb after breast cancer-related treatment, and compared with the healthy side, the edema dimension was more than 2cm.
- Age 18-75 years old;
- Edema stage Ⅰ to Ⅱ;
You may not qualify if:
- People with severe cognitive impairment;
- Bilateral lymphedema;
- Patients undergoing radiotherapy;
- Patients with uncontrolled tumors;
- Congestive heart failure and other comprehensive detumescence treatment contraindicated patients.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 5, 2025
First Posted
January 20, 2025
Study Start
November 13, 2024
Primary Completion
November 13, 2025
Study Completion
December 13, 2025
Last Updated
January 20, 2025
Record last verified: 2025-01
Data Sharing
- IPD Sharing
- Will share
The primary outcome mesurement will be shared.